ReviewBMC medicine2025
Molecular Mechanisms and Clinical Divergences in HPV-Positive Cervical vs. Oropharyngeal Cancers: A Critical Narrative Review.
Review in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Genetics and Molecular Mechanisms in Oral Squamous Cell Carcinoma: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- An overview of the DNA damage response in female reproductive system and breast cancers: A narrative review.International journal of reproductive biomedicine · 2026Review
- The role of liquid biopsy in the molecular characterization of HPV-related cancers.Folia microbiologica · 2026Review
- Post-Radiation PET Shows Higher Diagnostic Accuracy in HPV-Negative Head and Neck Cancers.Cancers · 2026Article
- Aurora kinase B as a therapeutic target in HPV-induced cervical cancer: mechanisms and future perspectives.Frontiers in oncology · 2026Review
- Therapeutic resistance in HPV-positive oropharyngeal squamous cell carcinoma: molecular mechanisms, clinical challenges, and precision strategies.Frontiers in genetics · 2026Review
- Comparative Diagnostic Performance of DNA Ploidy Analysis and p16/Ki67 Dual-Staining with Cytology in hrHPV-Defined Subgroups: A Single-Center Evaluation.Cancer management and research · 2026Article
- ROMO1 as a Diagnostic Biomarker in Cervical Neoplasia: Evidence from Normal, Pre-Invasive, and Invasive Lesions.Diagnostics (Basel, Switzerland) · 2025Article
- Unravelling the molecular crosstalk between Epithelial-Mesenchymal transition and human papillomavirus in oral cancer.Molecular biology reports · 2025Review
- Transcriptomic Differences Related to Neck Pain in Patients with Oropharyngeal Squamous Cell Carcinoma.Genes · 2025Article
- Identification of Bacterial Lipopolysaccharide-Related Molecular Subtypes and Development of a Four-Gene Prognostic Risk Model in Cervical Cancer.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) plays a pivotal role in the development of both cervical squamous cell carcinoma (CSCC) and oropharyngeal squamous cell carcinoma (OPSCC). However, these two cancers exhibit markedly different clinical behaviors. While HPV-positive OPSCC is distinguished by its heightened radiosensitivity, enabling effective treatment de-escalation and reduced toxicity, HPV-positive CSCC shows no such advantage, requiring aggressive therapeutic approaches similar to HPV-negative cases. This critical narrative review explores the limited molecular drivers currently known and the potential mechanisms underlying the divergent clinical responses of HPV-positive OPSCC and CSCC. Here, we discuss the role of HPV E6 and E7 oncoproteins in disrupting key tumor suppressor pathways, the impact of HPV DNA integration into the host genome, and the resulting genomic instability. By comparing the molecular mechanisms of these cancers, we aim to provide a comprehensive understanding of how these processes contribute to their distinct radiosensitivities and clinical outcomes. This review further highlights the gaps in the current research and proposes areas for future investigation, particularly in tailoring personalized treatment strategies for HPV-driven cancers. Understanding the differences in the molecular pathways that influence radiosensitivity in HPV-related cancers will not only enhance treatment strategies but also lead to improved patient outcomes and reduced treatment-associated toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.